Perfusio™ Has a Long History of Innovation

Our technology represents multiple years’ worth of development, experience and advancement on the part of our entrepreneurial team. Here’s a look at our company’s highlights:


  • Changed name from RFPi to Perfusio


  • Moved to new corporate office
  • Monte B. Tucker joins Perfusio as the new Chief Executive Officer
  • Finalized agreement with Cogmedix (Westborough, MA ) for commercial manufacturing
  • Established engineering partnerships with Nocturnal Product Development (Durham, NC), Triple Ring Technologies (Sunnyvale, CA), and Inov, Inc., (Tempe, AZ)
  • Operationalized the Perfusio ARMUS Cloud Repository and Surgeon Web Portal
  • Signed Nipro development agreement to expand Certes™ specifically for Japan


  • Commenced clinical outcome study at Vidant Medical Center in Greenville, North Carolina
  • Awarded SBIR Phase I and STTR Phase II grants totaling $1.75 million from the NIH to further develop Perfusio’s technology


  • Received Class II 510(k) clearance from the FDA for Certes™ in December
  • Selected as a 2018 MedTech Innovator from among 700 presenting


  • Signed license and investment agreement with Nipro Corporation for Certes in Japan
  • Received federal grant to study new clinical applications of Certes


  • Final Beta prototype design and build, with OEM suppliers and GMP
  • Build of pre-FDA clinical devices for first two clinical application areas; testing began at selected clinical sites
  • Secured $4 million in Series A financing in September 2016
  • TechConnect National Innovation Award Recipient


  • Signed technology license agreement with East Carolina University
  • Conducted additional experimental in vivo studies in collaboration with the Department of Comparative Medicine, with IACUC approval
  • Expanded potential clinical application areas with proof-of-concept studies in these experimental studies
  • Conducted additional human skin perfusion and blood flow studies for image metadata analyses


  • RFPi (now Perfusio) founded in May
  • Tested high-speed image acquisition and analysis using an improved pre-Alpha-version prototype
  • Conducted optics benchtop testing improved visualization and analysis algorithms on optics phantoms with microfluidic capacities
  • Built fully functional pre-Alpha-Plus prototype for experimental studies
  • Conducted experimental in vivo studies in collaboration with the Department of Comparative Medicine, with IACUC
  • Conducted human skin blood flow and perfusion studies